Growth differentiation factor 15 alleviates diastolic dysfunction in mice with experimental diabetic cardiomyopathy

Area of Science:

• Cardiovascular Science
• Metabolic Disease Research
• Endocrinology

Background:

• Growth Differentiation Factor 15 (GDF15) is recognized for its role in appetite regulation and weight management.
• Obesity is a significant risk factor for type 2 diabetes (T2D) and cardiovascular diseases, including heart failure.
• Elevated GDF15 levels are a known biomarker for heart failure, necessitating investigation into its direct cardiovascular effects.

Purpose of the Study:

• To investigate the impact of GDF15 treatment on diabetic cardiomyopathy in the context of type 2 diabetes.
• To determine if GDF15 influences cardiac pathology, specifically diastolic dysfunction, in preclinical models of T2D.

Main Methods:

• Utilized a mouse model of type 2 diabetes to assess the effects of GDF15 administration.
• Evaluated cardiac function, focusing on diastolic dysfunction, following GDF15 treatment.
• Investigated the role of cardiac inflammation and direct cellular responses to GDF15 in mediating observed effects.

Main Results:

• GDF15 treatment significantly alleviated diastolic dysfunction in mice with type 2 diabetes.
• The observed cardioprotective effects of GDF15 were independent of any significant weight loss in the treated animals.
• Cardiac inflammation was reduced following GDF15 treatment, suggesting an indirect mechanism of action.

Conclusions:

• GDF15 demonstrates therapeutic potential for mitigating diabetic cardiomyopathy, irrespective of weight reduction.
• The cardioprotection afforded by GDF15 appears to be mediated through indirect pathways, potentially involving reduced cardiac inflammation.
• Targeting GDF15 pathways could offer a dual benefit for managing obesity and associated cardiovascular complications like diabetic cardiomyopathy.